Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.
Store the approved injection at controlled room temperature and protect according to the current label; RUO powder requires lot-specific stability documentation
Solubility
Freely water-soluble; pharmaceutical-grade oral drops or IV solution; turns urine blue at research doses
Best-Effort Research Profile
Methylene blue is an FDA-approved oxidation-reduction agent for acquired methemoglobinemia. It accepts electrons from NADPH in erythrocytes and helps reduce methemoglobin to hemoglobin. Oral cognition, mitochondrial, and neurodegeneration uses remain investigational; small experimental studies and proprietary formulations do not establish a general cognitive or Alzheimer treatment protocol.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Research Profile
Half-Life
Approximately 24 hours per FDA prescribing information for oral dosing; multiphasic intravenous kinetics have shown an estimated terminal half-life closer to 5 hours in some studies, so the effective value depends heavily on route and dose.
Onset
Acute cognitive/fMRI effects reported with single low doses; AD trial effects assessed over months
Administration Routes (Research)
Intravenous (IV)
Reported Research Effects
Reduces methemoglobin in acquired methemoglobinemia
Experimental CNS and mitochondrial research remains formulation- and dose-specific
Reported Research Side Effects
Serotonin syndrome with serotonergic drugs
Hemolytic anemia in G6PD deficiency
Anaphylaxis
Confusion and dizziness
Nausea
Chromaturia and skin discoloration
Dose-related paradoxical methemoglobinemia
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Route-Specific Research Protocols
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Label / guidelineHuman studyCommunity onlyPreclinical onlyNot established
Intravenous (IV)Label / guideline
1 mg/kg over 5-30 minutes; a second 1 mg/kg dose may be given after 1 hour if required
Frequency / timing
Label-directed
Duration / setting
Acute treatment
Technique
IV
Evidence
Regulatory label
Context: PROVAYBLUE prescribing information
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Research Interactions
Flagged Avoid / Caution Combinations (Research)
Serotonergic drugs
G6PD deficiency
Severe renal impairment without specialist review
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
Research Notes
FDA approval is for acquired methemoglobinemia. Low-dose oral cognitive or longevity schedules are unapproved and were removed; methylene blue can precipitate serotonin syndrome and hemolysis in G6PD deficiency.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.